近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

平成28年度

巻頭言

平成28年度
ライフサイエンス研究所紀要発刊によせて
前研究所長（平成30年10月1日の人事異動により）
奥野　清隆（外科学教授 下部消化管部門教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織で、医学部からは独立した研究施設ですが、医学部の建物内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、共同兼任の状態にあることから、医学部の研究に寄与するところが大きな施設といえるでしょう。
　私立大学医学部や私立医科大学で基礎的な研究に専念する医学部出身者は元来多くありませんでしたが、新臨床研修制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師は非常に少なくなってきました。私どものライフサイエンス研究所も研究者不足、若い医師の研究志向の低下の影響をうけていると考えられます。
　しかし、時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことと考えます。基礎系および臨床系の多くの教室の多大な御尽力と、研究所の技術員の奮闘に敬意を表するとともに、引き続いての御協力をお願いする次第です。

平成28年度ライフサイエンス研究所紀要

病理学教室（伊藤　彰彦　教授）

  1. T. Kato, K.Oka, T. Nakamura, A. Ito
    Decreased expression of Met during differentiation in rat lung
    European Journal of Histochemistry, 60: 2575, 2016.

免疫学教室（宮澤　正顯　教授）

  1. Takeshi Yoshikawa, Jianfeng Wu, Motoyuki Otsuka, Takahiro Kishikawa, Nobumi Suzuki, Akemi
    Takata, Motoko Ohno, Rei Ishibashi, Mari Yamagami, Ryo Nakagawa, Naoya Kato, Masaaki Miyazawa, Jiahuai Han, and Kazuhiko Koike
    Repression of MicroRNA Function Mediates Inflammation-associated Colon Tumorigenesis
    Gastroenterology, 152: 631-43, 2017.
  2. Shiki Takamura, Hideki Yagi, Yoshiyuki Hakata, Chihiro Motozono, Sean R. McMaster, Tomoko
    Masumoto, Makoto Fujisawa, Tomomi Chikaishi, Junko Komeda, Jun Itoh, Miki Umemura, Ami Kyusai, Michio Tomura, Toshinori Nakayama, David L. Woodland, Jacob E. Kohlmeier, and Masaaki Miyazawa
    Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance J Exp Med, 213(13): 3057-73, 2016.
  3. 宮澤 正顯, 博多 義之, 武田 英里, 李 君, 河原 佐智代
    特集：DNA/RNA編集研究の新たな眺望
    マウスAPOBEC3の生理機能と分子進化
    生化学 第88巻 第5号, pp.582‒592（2016）

公衆衛生学教室（伊木　雅之　教授）

  1. Katsuyasu Kouda, Kumiko Ohara, Harunobu Nakamura, Yuki Fujita, Masayuki Iki
    Predicting bone mineral acquisition during puberty: data from a 3-year follow-up study in Hamamatsu, Japan
    J Bone Miner Metab, 35: 185–191, 2017
  2. Katsuyasu Kouda, Harunobu Nakamura, Kumiko Ohara, Yuki Fujita, and Masayuki Iki
    Increased Ratio of Trunk-to-Appendicular Fat and Decreased Adiponectin:
    A Population-Based Study of School Children in Hamamatsu, Japan
    Journal of Clinical Densitometry: Assessment & Management of Musculoskeletal Health, 20(1), 66–72, 2017

ゲノム生物学教室（西尾　和人　教授）

  1. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.
    Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
    ESMO Open, 1(4): e000063, 2016.
  2. Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.
    Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
    Annals of Oncology 28: 136–41, 2017
  3. Matsuo N, Azuma K, Sakai K, Hattori S, Kawahara A, Ishii H, Tokito T, Kinoshita T, Yamada K, Nishio K, Hoshino T.
    Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
    Sci Rep, 6: 36458, 2016.
  4. Mizukami T, Sakai K, Naruki S, Taniyama T, Horie Y, Izawa N, Tsuda T, Fujino T, Boku N, Yasuda H, Fukunaga T, Nakajima T, Nishio K.
    Identification of a FGFR3-TACC3 fusion in esophageal cancer.
    Annals of Oncology 28: 437–8, 2017
  5. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
    FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
    Cancer Sci, 107:1667-76, 2016.
  6. Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
    MEK inhibitors against MET-amplified non-small celllung cancer.
    Int J Oncol, 49: 2236-44, 2016.
  7. Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.
    A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G.
    Cancer Sci, 2016. in press.
  8. De Velasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    Oncotarget, 7(13): 15959-76, 2016.
  9. Nagai H, Oiso N, Tomida S, Sakai K, Fujiwara S, Nakamachi Y, Kawano S, Kawada A, Nishio K, Nishigori C.
    Epidermolysis bullosa simplex with mottled pigmentation with noncicatricial alopecia: identification of a recurrent p.P25L mutation in KRT5 in four affected family members. Br J Dermatol, 17 4(3): 633-5, 2016.
  10. Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, KanazawaA, Takeda Y, Takemura S, Kubo S, Nishio K.
    Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
    Oncotarget, 7(31): 49091-8, 2016.
  11. Fujita Kimura M, Sato H, Takata T, Ono N, Nishio K.
    Characterization of the cytotoxic activity of [2] rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells.
    Arch Pharm Res, 39 (6): 825-32, 2016.
  12. Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y , Isogai N, Nishio K, Nakagawa K.
    Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
    Invest New Drugs, 34 (3): 394-6, 2016.
  13. Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
    Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
    Clin Cancer Res, 22(14): 3663-71, 2016.
  14. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
    HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
    Oncotarget, 7( 3): 3453-60, 2016.
  15. Murao T, Shiotani A, Fujita Y, Yamanaka Y, Kamada T, Manabe N, Hata J, Nishio K, Haruma K.
    Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.
    JG astroenterol Hepatol, 31 (1): 99-06, 2016.
  16. Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T.
    Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Lung Cancer, 91 : 36-40, 2016.
  17. Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, De Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K.
    Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
    Mol Carcinog, 56: 106-117, 2016.
  18. Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Janne PA, Nakagawa K.
    Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Oncogene, 35 (7): 878-86, 2016.
  19. Ohira T, Sakai K, Matsubayashi J, Kajiwara N, K akihana M, Hagiwara M, Hibi M, Yoshida K, Maeda J, Ohtani K, Nagao T, Nishio K, Ikeda N.
    Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
    Cancer Sci, 107: 1660-6, 2016.
  20. Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
    Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan
    oncology group 8014LTR study).
    Oncotarget, 7(36): 58492-9, 2016.
  21. Banno E, Togashi Y, Nakamura H, Chiba M, Kobayashi Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
    Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S7681: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Cancer Sci, 107(8): 1134-40, 2016.
  22. 22. Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, De Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Mol Cancer Ther, 15 (8): 1988-97, 2016.
  23. Takeda M, Sakai K, Okamoto K, Hayashi H, Tanaka K, Shimizu T, Nishio K, Nakagawa K.
    Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.
    Ann Oncol, 27 (4): 748-50, 2016.
  24. Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T.
    Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
    Cancer Sci, 10 7(4): 461-8, 2016.
  25. Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y, Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, Kudo M.
    Impact of Tight Junction Protein ZO-l and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.
    Dig Dis, 34 (6): 702-07, 2016.
  26. Sato K, Suda K, Shimizu S, Sakai K, Mizuuchi H, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.
    Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
    PLoS One, 11(4): e0154186, 2016.

総説

  1. 富樫庸介，西尾和人
    世代別(第1、2、3)EGFR-TKIの耐性化機構 がん分子標的治療 14(2):237-43，2016.
  2. 坂井和子，西尾和人
    【いま、がんのクリニカルシークエンスがおもしろい!】 cfDNAによる遺伝子変異検出の臨床応用へ向けたデジタルPCR技術　実験医学　34(18):3074-3080，2016.
  3. 西尾和人
    【肺癌診断・治療の最前線】肺癌におけるクリニカルシーケンシング
    呼吸器内科　29(3):185-90，2016.
  4. 西尾和人
    マルチ診断薬による肺癌最適化医療に向けての取り組み　肺癌　56(1): 48-54, 2016.
  5. 西尾和人
    【婦人科がん治療の新機軸】次世代シーケンサーを用いたコンパニオン診断、クリニカルシーケンシング　産科と婦人科　83(1):55-61，2016.
  6. 西尾和人, 坂井和子
    Liquid biopsyによる分子標的薬の治療感受性の予測　血液内科　72(1): 155-60, 2016.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.